Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of FF/UMEC/VI in Healthy Chinese Subjects
NCT02837380Phase 1Completed
- Sponsor
- GSK
- Start
- Sep 2016
- Primary completion
- Nov 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluticasone, umeclidinium and vilanterol in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Primary endpoints: Maximum observed concentration of FF, UMEC and VI after single inhaled dose at Day 1, Time of occurrence of Cmax of FF, UMEC and VI after single inhaled dose at Day 1 and 15 more. Started Sep 2016; status: completed.
02
Drugs
fluticasoneumeclidiniumvilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02837380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02837380.